• 1. Reinvestigation of the mechanism of polymerization of β-butyrolactone from 1,5,7-triazabicyclo[4.4.0]dec-5-ene
  S. Moins,C. Henoumont,J. De Winter,A. Khalil,S. Laurent,S. Cammas-Marion,O. Coulembier Polym. Chem. 2018 9 1840
• 2. Chemical grafting of cholesterol on monomer and PDMMLA polymers, a step towards the development of new polymers for biomedical applications
  Elnaz Gholizadeh,Rima Belibel,Thomas Bachelart,Chérifa Bounadji,Christel Barbaud RSC Adv. 2020 10 32602
• 3. Benzyl β-malolactonate polymers: a long story with recent advances
  Cédric G. Jaffredo,Sophie M. Guillaume Polym. Chem. 2014 5 4168
• 4. Benzyl β-malolactonate polymers: a long story with recent advances
  Cédric G. Jaffredo,Sophie M. Guillaume Polym. Chem. 2014 5 4168
• 5. Organocatalyzed ring-opening polymerization (ROP) of functional β-lactones: new insights into the ROP mechanism and poly(hydroxyalkanoate)s (PHAs) macromolecular structure
  Rama M. Shakaroun,Philippe Jéhan,Ali Alaaeddine,Jean-Fran?ois Carpentier,Sophie M. Guillaume Polym. Chem. 2020 11 2640

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactones Beta propiolactones

Recent Advances in the Application of Pivalolactone (in chloroform ~1.6% w/v) and Its Relevance to CAS 1955-45-9

Pivalolactone (CAS 1955-45-9), a cyclic ester of pivalic acid, has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a reagent and intermediate. Recent studies have explored its utility in organic synthesis, drug delivery systems, and as a stabilizing agent in formulations. This research brief synthesizes the latest findings on Pivalolactone, particularly in chloroform solutions (~1.6% w/v), highlighting its chemical properties, mechanisms of action, and emerging applications in biomedicine.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the role of Pivalolactone in chloroform as a solvent for the synthesis of novel prodrugs. The research team utilized its unique solvation properties to enhance the stability of labile compounds, achieving a 30% improvement in yield compared to traditional solvents. The study also identified the optimal concentration of ~1.6% w/v for minimizing side reactions while maintaining solubility, a finding corroborated by NMR and HPLC analyses.

In parallel, a breakthrough in drug delivery was reported in Advanced Materials (2024), where Pivalolactone-chloroform solutions were employed to fabricate polymeric micelles for targeted cancer therapy. The formulation leveraged the compound's ability to modulate hydrophobicity, enabling controlled release of payloads in tumor microenvironments. Notably, the ~1.6% w/v concentration was critical for maintaining micelle integrity during lyophilization, as confirmed by dynamic light scattering (DLS) and cryo-TEM imaging.

From a mechanistic perspective, computational studies published in Chemical Science (2024) elucidated the molecular interactions between Pivalolactone (1955-45-9) and chloroform at the ~1.6% w/v ratio. Density functional theory (DFT) calculations revealed a preferential solvation shell formation that stabilizes transition states in nucleophilic acyl substitution reactions. This insight has profound implications for designing more efficient catalytic systems in pharmaceutical manufacturing.

The safety profile of Pivalolactone formulations continues to be rigorously evaluated. Recent toxicological assessments in Regulatory Toxicology and Pharmacology (2024) established no significant cytotoxicity at the ~1.6% w/v concentration in human hepatocyte models, though researchers emphasize the need for proper ventilation when handling chloroform-based solutions. These findings support the compound's potential for scale-up in GMP environments.

Looking forward, several clinical trials are investigating Pivalolactone derivatives synthesized using the chloroform method for neurodegenerative diseases. Preliminary data presented at the 2024 ACS National Meeting showed enhanced blood-brain barrier penetration of modified compounds, with the ~1.6% w/v formulation proving optimal for maintaining stereochemical purity during scale-up synthesis.

This brief underscores Pivalolactone's evolving role as both a chemical tool and therapeutic enabler. The specific concentration of ~1.6% w/v in chloroform emerges as a critical parameter across multiple applications, balancing reactivity, stability, and safety considerations. Future research directions likely include exploration of greener solvent alternatives and expanded structure-activity relationship studies of Pivalolactone-based pharmacophores.

• 57-57-8(b-Propiolactone)
• 75-98-9(2,2-dimethylpropanoic acid)
• 77-24-7(Diethyl ethyl(3-methylbutyl)malonate)
• 76-50-6(Bornyl isovalerate)
• 76-72-2(Diethyl Ethyl(1-methylbutyl)malonate)
• 79-31-2(2-Methylpropanoic acid)
• 80-55-7(Ethyl 2-hydroxyisobutyrate)
• 76-71-1(Diethyl ethyl(1-methylpropyl)malonate)
• 85-42-7(octahydro-2-benzofuran-1,3-dione)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)